First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report (Q34135007)

31 July 2017

1 reference

title

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report (English)

1 reference

31 July 2017

metastatic breast cancer

1 reference

C Vogel

1

1 reference

31 July 2017

M A Cobleigh

2

1 reference

31 July 2017

D Tripathy

3

1 reference

31 July 2017

J C Gutheil

4

1 reference

31 July 2017

L N Harris

5

1 reference

31 July 2017

L Fehrenbacher

6

1 reference

31 July 2017

D J Slamon

7

1 reference

31 July 2017

M Murphy

8

1 reference

31 July 2017

W F Novotny

9

1 reference

31 July 2017

M Burchmore

10

1 reference

31 July 2017

S Shak

11

1 reference

31 July 2017

S J Stewart

12

1 reference

31 July 2017

Genentech H0650 study investigators

13

1 reference

31 July 2017

1 January 2001

1 reference

European Journal of Cancer

31 July 2017

1 reference

31 July 2017

37 Suppl 1

1 reference

31 July 2017

S25-9

1 reference

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900405-6

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900405-6

7 January 2021

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900405-6

7 January 2021

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900405-6

7 January 2021

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900405-6

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900405-6

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900405-6

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900405-6

7 January 2021

10.1016/S0959-8049(00)00405-6

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/y66ji7ux6fgfvkvnx634kkz6du

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_y66ji7ux6fgfvkvnx634kkz6du

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/y66ji7ux6fgfvkvnx634kkz6du

30 July 2022

mapped directly with Wikidata item

1 reference

reason for deprecated rank

31 July 2017

incorrect identifier value

0 references

1 reference

https://api.fatcat.wiki/v0/release/y66ji7ux6fgfvkvnx634kkz6du

30 July 2022